Compare LYFT Inc (LYFT) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LYFT Inc vs Moderna, Inc. — how do they compare? LYFT Inc trades at $16.18 (market cap $5.90B), while Moderna, Inc. trades at $195.7 (market cap $78.44B). The key difference: Moderna, Inc. is far larger — about 13.3× LYFT Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, LYFT Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold LYFT Inc for 47 Days and Moderna, Inc. for 59 Days on average.
| LYFT | MRNA | |
|---|---|---|
Market Cap | $5.90B | $78.44B |
Volume | 9,741,129 | 14,597,511 |
Sector | Technology | Health |
52-Week High | $24.57 | $203.46 |
52-Week Low | $12.65 | $22.36 |
Typical Hold Time | 47 Days | 59 Days |
Enterprise Value | $5.37B | $74.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lyft trades at $16.13, up 2.35% on the day, with a bullish technical signal from moving averages but a neutral stance from oscillators. The company reported strong revenue growth to $6.32B in 2025 and a net income of $2.84B, though recent quarterly EPS results have missed expectations. Positive developments include European expansion and a partnership with Sphere, while a $272.5M legal settlement poses a headwind.
The outlook is mixed; low P/E and P/S ratios suggest undervaluation, and analyst consensus targets $18.07, but execution risks and competitive pressures remain. Earnings consistency is key for sustained upside, with the stock offering value if growth momentum continues despite near-term volatility.
Moderna (MRNA) trades at $196.48, up 4.81% amid Nasdaq-100 inclusion news, though it remains well below the analyst consensus target of $115.70. The stock shows bullish technical momentum with recent earnings beats, but faces fundamental challenges with negative profit margins and declining revenue from pandemic-era highs. The company's cash flow improved in 2025, turning positive for the first time since 2022, while its pipeline, including oncology vaccines, attracts investor interest despite valuation concerns.
Outlook: Near-term momentum from index fund buying and pipeline updates may support the stock, but high valuation multiples and persistent losses pose significant risks. Long-term growth depends on successful commercialization of non-COVID products, with current prices reflecting optimistic scenarios. Investors should weigh the potential of the mRNA platform against execution risks and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
